Targeting Mitochondrial Dysfunction

Our lead product, Imeglimin, is in Phase 3 development in Japan and has successfully completed Phase 2 development in the U.S. and EU.

View Candidate
Targeting Mitochondrial Dysfunction

Innovative Pipeline of First-In-Class Products

Our candidates are based on disease-modifying mechanisms of action that offer the potential for safer and more effective therapies for type 2 diabetes and NASH.

View Pipeline
Innovative Pipeline of First-In-Class Products

Backed by Strong Leadership

Our highly-experienced clinical and regulatory teams possess the know-how and experience to successfully develop products within our pipeline.

Meet Our Team
Backed by Strong Leadership

Latest News

Poxel Announces Presentation of PXL065 Data at the 2019 NASH-TAG Conference

Presentation highlighted different stereoisomer properties of pioglitazone and other thiazolidinediones (TZDs) Data observed suggests a more favorable profile for PXL065…

Read this Press Release: Poxel Announces Presentation of PXL065 Data at the 2019 NASH-TAG Conference
Click here to show the previous slide Click here to show the next slide